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Acyclovir [9-(2-hydroxyethoxymethyl)guanineI (ACV), a potent antiviral com-
pound, was phosphorylated to the same extent by extracts from untreated and
iododeoxyuridine-treated Epstein-Barr virus-containing latent D98/HR-1 somatic
hybrid cells. ATP was the preferred phosphate donor over other nucleoside
triphosphates. The cytosol extract from D98/HR-1 cells effected optimum phos-
phorylation of thymidine at pH 8.0, whereas ACV was phosphorylated equally
well over a wide pH range. Electrophoretic analysis of thymidine kinase-,
deoxycytidine kinase-, and ACV-phosphorylating activities from both untreated
and iododeQxyuridine-treated cell extracts displayed identical properties. A small
part (5 to 10%o) of the loaded ACV-phosphorylating activity seemed to migrate
with the deoxycytidine kinase activity from cytosol. dTTP and dCTP, at relatively
high concentrations, partially inhibited ACV-phosphorylating activity. The results
suggest that Epstein-Barr virus does not code for its own thymidine kinase and
that phosphorylation ofACV in Epstein-Barr virus-producing cells is carried out
by miultiple or as yet unidentified ATP-dependent nonspecific cellular phospho-
transferases.
The acyclic nucleoside analog acyclovir [9-(2-
hydroxyethoxymethyl)guanine] (ACV) is cur-
rently considered as one of the drugs for the
topical treatment of certain herpes simplex virus
(HSV) infections, such as primary genital herpes
and generalized cutaneous herpes in immuno-
compromised patients (10). Biochemical and ge-
netic studies of its mechanism of action in HSV
systems have shown that the compound is con-
verted to its triphosphate form; the first step of
phosphorylation is carried out by virus-specified
thymidine (TdR) kinase (4, 10). The monophos-
phate thus formed is subsequently converted to
triphosphate by host enzymes (17). The triphos-
phate form specifically inhibits the DNA poly-
merase of HSV by competing with dGTP (10).
Cells infected with TdR kihase-negative virus
were unable to phosphorylate ACV to a great
xtent, and hence the drug was ineffective.
Reports from this laboratory (6, 7) show that
ACV is effective in inhibiting Epstein-Barr virus
(EBV) replication. However, in contrast to
HSV, the amount of phosphorylated drug
formed in vivo in EBV-infected cells is minimal
and identical in both infected and noninfected
cells (5). These observations led us to analyze
the process ofACV phosphorylation in vitro in a
latent EBV DNA-containing cell line (D98IHR-
1, lOa).
Treatment of D98/HR-1 somatic cell hybrids
with iododeoxyuridine (IUdR) gives rise to the
induction of EBV-associated DNA polymerase
with a subsequent induction of -viral DNA syn-
thesis and the production of EBV particles (16).
The induction of viral DNA synthesis in IUdR-
treated cells can be efficiently inhibited by ACV
(15). This system was ideally suited for our
purpose inasmuch as we could follow the induc-
tion of EBV-associated DNA polymerase activi-
ty as an internal marker while analyzing the
extent of ACV phosphorylation and TdR kinase
activity. This exercise was necessary in view of
the conflicting reports in favor of both existence
and nonexistence of EBV-associatod TdR ki-
nase (3, 19, 20). Moreover, in vaccinia virus and
herpesvirus saimiri systems, ACV is not at all
effective despite the presence of virus-specified
TdR kinase (10, 11). These findings raised the
question of whether the presence of virus-speci-
fied TdR kinase is essential for ACV to be
effective. The studies reported in this paper are
directed at answering this question.
MATERILUS AND METHODS
Cels. Burkitt hybrid cells, D98/HR-1, clone 1, se-
lected in hypoxanthine-aminopterin-ihymidine-con-
taining medium were a gift of Ronald Glaser, Ohio
State University, Columbus.
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Chemicals. [14C]ACV (54 mCi/,Lmol) and unlabeled
ACV were gifts of G. Elion, Burroughs Wellcome Co.,
Research Triangle Park, N.C. Nucleosides and their
triphosphates were obtained from P-L Biochemicals,
Milwaukee, Wis. ATP was purchased from Sigma
Chemical Co., St. Louis, Mo. Tetrahydrouridine was
provided by Y.-C. Cheng, Cancer Research Center,
University of North Carolina, Chapel Hill.
Treatment of cells with IUdR. Cells were seeded in
minimal essential medium and treated with IUdR for 3
days as described elsewhere (15).
Preparation of phosphorylating activity. Mock-treat-
ed and IUdR-treated cells were processed as follows.
Cells were suspended in a buffer containing 10 mM
KCI, 0.0015 M MgCl2, 10 mM Tris (pH 7.4), and 0.25
M sucrose and kept suspended for 20 min at 0°C.
Phenylmethylsulfonyl fluoride was then added to a
final concentration of 1 mM, and the cells were
disrupted with a Dounce homogenizer. The suspen-
sion was centrifuged at 800 x g for 5 min. The pellet
formed was used as the source of nuclei. KCI was
added to the supernatant fluid to a final concentration
of 0.15 M, and ATP and P-mercaptoethanol were
added to final concentrations of 10 and 5 mM, respec-
tively. The supernatant fluid was centrifuged at
105,000 x g for 2 h. The clear supernatant fluid formed
was dialyzed for 8 to 12 h against a dialysis buffer (10
mM Tris [pH 7.4], 0.15 M KCI, 10 mM P-mercaptoeth-
anol, 10 mM ATP, 10 mM MgCl2, 20% glycerol, 1 mM
phenylmethylsulfonyl fluoride). The dialyzed fraction
was clarified by centrifugation and was used as the
cytosol extract. Total cell extract was prepared by
suspending the cells in the same dialyzing buffer and
then sonicating them. The rest of the procedure was
the same as for the cytosol prejparation. The washed
nuclear pellet used for DNA polymerase assays was
processed as described before (8).
Enzyme assays. Assays for TdR kinase were carried
out as follows. The reaction volume of 100 ,u con-
tained 100 mM Tris (pH 7.5), 10 mM MgCl2, 10 mM
ATP, 3 mM 3-mercaptoethanol, 2 mM NaF, 100 FM
[3H]TdR (10 cpm/pmol), and the required amount of
enzyme. The reactions were carried out at 37'C for 30
min. Samples (50 Fl each) of the reaction mixture were
removed and applied to DE-81 paper disks. The papers
were washed three times with 0.01 M ammonium
acetate, followed by two rinses with water and with
95% alcohol. Filters were dried, and radioactivity was
determined in toluene-based solvent.
For deoxycytidine (CdR) kinase assay the methods
were the same except that [3H]CdR was used as the
substrate, and the reaction mixture contained 0.2 mM
tetrahydrouridine.
The reaction mixture for assay of ACV phosphor-
ylation was exactly the same as for the TdR kinase
assay except that 500 ,uM [14C]ACV (54 cpm/pmol)
was used as the acceptor nucleoside. Assays were
carried out for 120 min unless otherwise stated. For
determination of radioactivity, the DE-81 papers were
rinsed three times with 0.001 M ammonium acetate,
three times with 70%o alcohol containing 1 mM guano-
sine and 0.001 M ammonium acetate, and three times
each by washing under pressure filtration with water
and with 70%o alcohol.
PAGE. Polyacrylamide gel electrophoresis (PAGE)
was essentially the same as described elsewhere (13)
except that ammonium persulfate was used instead of
riboflavin for gel polymerization. Samples (50 ,ul each)
in 20%o glycerol-0.001% bromophenol blue were ap-
plied to the gel. After PAGE, the gels were sliced and
assayed by dipping each slide in 100 ,ul of reaction
mixture. The incubations were for 3 at 37°C for ACV
phosphorylation and 1 for TdR and CdR phosphoryla-
tion.
RESULTS
ACV- and TdR-phosphorylating activities in
IUdR-treated D981H1-1 cytosol extracts. ACV
was phosphorylated Equally by both untreated
and lUdR-treated cytosol extracts (Fig. 1). The
reaction was linear over a period of 120 min.
However, the rate of ACV phosphorylation was
100 to 150 times lower than the rate of TdR
phosphorylation. The phosphorylation was
mostly ATP dependent (Table 1) in both mock-
treated and IUdR-treated cytosol extkacts.
To ascertain whether TdR kinase present in
the cytosol extract plays any role in the phos-
phorylation, ACV and TdR kinase assays were
carried out at different pHs. TdR was phosphor-
ylated maximally at pH 8.0 and had a: sharp pH
optimum (Fig. 2). In contrast, phosphorylation
of ACV had very broad pH optitna in both
IUdR-treated and untreated extracts.
PAGE analysis of TdR kinase-, CdR kinase-,
and ACV-phosphorylating activity. For further
insight into the different deoxynucleoside kinase
activities in IUdR-treated D98/HR-1 cells, th-




























FIG. 1. Kinetics of phosphorylation of ACV and
TdR by the cytosol extracts from IUdR-treated and
untreated D98/HR-1 cells. ACV phosphorylation with
untreated (A) and IUdR-treated (A) cellular cytosol
extracts and TdR phosphorylation with untreated (0)
and IUdR-treated (0) cellular cytosol extracts were
carried out as described in the text.
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TABLE 1. Phosphate donor specificity for ACV
phosphorylationa













a Assays were canied out with cytosol extracts.
treated cells were analyzed by PAGE (Fig. 3).
The results indicated that in both treated (Fig.
3A) and untreated (Fig. 3B) extracts there were
tvo TdR kinase isozymes with different electro-
phoretic mobilities. The activity with slower
electrophoretic mobility (0.15) is cytosol kinase,
whereas mitochondrial kinase moved with an












































FIG. 3. PAGE analysis of total cellular extracts
from IUdR-treated (A) and untreated (B) D98/HR-1
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FIG. 2. Determination of optimum pH for phos-
phorylation of ACV and TdR. ACV phosphorylation
with untreated (O) and IUdR-treated (A) cellular cyto-
sol extracts and TdR phosphorylation with untreated
(0) and IUdR-treated (A) cellular cytosol extracts
were carried out at different pHs.
these two activities was checked by differential
inhibition with dTTP and dCTP and by phos-
phate-donor specificities (data not presented)
(13). Interestingly, we did not detect any other
TdR kinase activity peaks in IUdR-treated cells.
These results indicated that EBV, unlike HSV,
does not code for its own distinct TdR kinase as
reported earlier (3).
In addition to cellular TdR-phosphorylating
activity, mitochondrial TdR kinase also has CdR
kinase activity (14). In addition, there is another
activity peak with an electrophoretic mobility of
0.85 to 0.88 that can phosphorylate CdR. This
activity has been designated as cytosol CdR
kinase (12). In the PAGE analysis, a small
fraction (5 to 10%) of the loaded ACV-phosphor-
ylating activity coincided with the cytosol CdR
kinase activity in both treated and untreated
cells, whereas none of the TdR kinase activities
could phosphorylate ACV.
Effect of end product inhibitors on ACV phos-
phorylation. Reports from several laboratories
indicate that dTTP and dCTP are the two key
deoxynucleoside triphosphates known to inhibit
both cellular and viral TdR kinase activities
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strongly (12, 13). However, in our hands dTTP
and dCTP each at a concentration of 1 mM
inhibited ACV-phosphorylating activity only
partially (Table 2). The extent of inhibition was
similar in both IUdR-treated and untreated cells.
DISCUSSION
This report substantiates our recent infer-
ences (7, 19) that all herpesviruses do not have
to have their own TdR kinase for ACV to be
effective. This situation is in contrast to the HSV
system in which viral TdR kinase plays an
essential role in the phosphorylation of ACV
(10). The occasional induction of total cellular
TdR kinase activity in superinfected Raji cells
(19, 20) is probably dependent on the cell cycle
and the stages at which the cells are infected.
The results described in this paper with EBV are
in agreement with the findings of Burn et al. (2)
who showed that mouse cytomegalovirus, which
does not code for its own TdR kinase (18), is as
sensitive as HSV to ACV.
In view of the reports (1, 12) that cytosol CdR
kinase can phosphorylate a large variety of
nucleosides other than CdR and that the enzyme
has other allosteric sites in addition to the CdR-
phosphorylating site, it is not unlikely that cyto-
sol CdR kinase might phosphorylate ACV to
some extent. The results (Fig. 3) indicate that a
small portion (5 to 10%) of the ACV-phosphory-
lating activity loaded on the gel seems to migrate
with cytosol CdR kinase activity. We could not
account for the remaining activity. However, 80
to 85% of TdR kinase activity loaded on the gel
could be accounted for. Whether this slight
disparity was due to inactivation of the rest of
the ACV-phosphorylating activity or to nonmi-
gration of other enzymes into the gel under this
electrophoretic condition is not known.
The conclusion that ACV is not phosphorylat-
ed by virus-specified TdR kinase in lymphoblas-
toid cells came from the studies with nucleoside
triphosphate inhibition specificity (Table 2).
Moreover, phosphorylation ofACV over a wide
range of pH (Fig. 2) also supported this conclu-
TABLE 2. Effect of dTTP and dCTP on ACV-
phosphorylating activity from cytosol of IUdR-
treated and untreated D98/HR-1 cellsa
pmol of ACV phosphorylated
Triphosphate per mg of protein
Untreated IUdR treated
ATP 923 971
ATP + dTTP (1 mM) 413 419
ATP + dCTP (1 mM) 417 491
None
a Assays were carried out in the presence of 10 mM
ATP-Mg2+.
sion. Partial inhibition of ACV phosphorylation
by dTTP and dCTP was probably due to the
intricate mechanism of action of these triphos-
phates toward other nucleoside-phosphorylating
activities of the DNA biosynthesis pathway (12).
Our unpublished data on the partial inhibition
of ACV-phosphorylating activity by deoxyguan-
osine, TdR, and CdR are in agreement with the
findings of Davidson et al. (9), who showed that
cellular toxicity in vivo by ACV can be reversed
by the exogenous addition of the above deoxy-
nucleosides. Direct analysis with purified en-
zymes should throw more light onto this ques-
tion, but low levels ofACV phosphorylation and
the relatively unstable nature of the activity
might hinder the execution of such a study.
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